Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.

ABSTRACT: Patients with nucleophosmin 1 (NPM1)-mutated acute myeloid leukemia (AML) without a FLT3-internal tandem duplication mutation are considered to have favorable-risk disease that may be cured with intensive chemotherapy (7+3; IC) alone. As patients age, the potential for cure without transplant is counterbalanced by morbidity associated with IC. Venetoclax combined with a hypomethylating agent (VEN/HMA) is approved for patients aged ≥75 years or those ineligible for IC, and the regimen is therefore frequently utilized in patients between 60 and 75 years of age. The differences in outcomes between patients with NPM1-mutated, favorable-risk AML who receive IC and VEN/HMA are unknown. We performed a retrospective analysis of patients aged 60 to 75 years with favorable risk,

SUBMITTER: Zale AD 

PROVIDER: S-EPMC12423340 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature